Plasmodium falciparum malaria

This early-stage trial tests a new malaria vaccine called PfSPZ-LARC2 in up to 22 healthy adults who have never had malaria. The vaccine uses live but genetically weakened malaria parasites that stop developing late in the liver, aiming to trigger a stronger immune response than …

This trial tests an experimental malaria vaccine called RH5.2-VLP, given with an adjuvant (Matrix-M) to boost the immune response. Healthy adults aged 18–45 receive three doses, and some volunteers are later exposed to malaria parasites in a controlled setting to see if the vacci…

This study tested two different malaria vaccines—one targeting the blood stage and one the liver stage—alone and in combination. 107 healthy adults and infants in The Gambia received the vaccines to check safety and immune response. The goal is to see if combining them offers bet…

This study tested two experimental malaria vaccines in 345 healthy Indonesian soldiers deployed to a malaria-endemic region. One vaccine uses weakened malaria parasites, and the other uses live parasites with a preventive drug. The goal was to see if either vaccine could safely p…

This study tested a new malaria vaccine made from genetically weakened parasites that stop growing in the liver and cannot cause blood-stage infection. The goal was to see if it is safe and triggers a strong immune response. The trial involved 75 healthy adults and children in Bu…

This study tested an experimental RNA-based vaccine called BNT165e to see if it can prevent malaria. 163 healthy adults who had never had malaria received either the vaccine or a placebo. Researchers measured safety, immune responses, and whether the vaccine protected against a c…

This study tested the RTS,S/AS01E malaria vaccine in nearly 78,000 young children in Sub-Saharan Africa. Researchers checked the vaccine's safety and how well it prevents malaria. The goal was to see if the vaccine can be safely used in routine immunization programs to protect ch…

This early-stage trial tested a new malaria vaccine called AMA1-DiCo in 66 healthy adults—some in Europe never exposed to malaria, and some in Africa who were. The vaccine was given with one of two adjuvants (GLA-SE or Alhydrogel) to boost immune response. The main goal was to ch…

This early-stage trial tested an experimental RNA vaccine called BNT165b1 in 60 healthy adults to see if it is safe and triggers an immune response against malaria. The vaccine uses messenger RNA to teach the body to recognize a key malaria protein. The study was completed and fo…

This trial tests whether giving children with uncomplicated malaria a triple combination of artemisinin-based drugs works better than the standard two-drug treatment. The goal is to see if using three drugs together can delay the malaria parasite from becoming resistant. Children…

This study tested a new two-drug combination (KAF156 plus a special form of lumefantrine) in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment safely clears the parasite and prevents the infection from coming back. The approac…

This study tested a combination of two anti-malarial drugs, cipargamin and KLU156, in 60 people with uncomplicated Plasmodium falciparum malaria. Participants were at least 12 years old and had a confirmed infection. The main goal was to see if the drugs could clear the malaria p…

This study tested a new intravenous drug called cipargamin in 254 adults and children with severe malaria. The goal was to find a safe and effective dose that quickly clears the malaria parasite, especially in areas where standard treatments are becoming less effective. Researche…

This study tested whether a single dose of two antimalarial drugs, M5717 and pyronaridine, can clear the malaria parasite from the blood and prevent new infections in people who have the parasite but no symptoms. 192 adults and adolescents in malaria-endemic areas took part. The …

This study looked at whether finding and treating low-density malaria infections (infections with very few parasites) in children can improve their health and well-being over time. 600 children in Tanzania, aged 6 months to 10 years, took part. The goal was to see if this approac…

This study tested a new malaria drug called KLU156 in over 1,700 adults and children with uncomplicated malaria. It compared KLU156 to a standard treatment, Coartem, to see if it works as well. Some participants continued taking KLU156 for up to two years to check its safety with…

This study tested a monoclonal antibody called TB31F in 167 adults and children in Mali who are regularly exposed to malaria. The goal was to see if the antibody is safe and can reduce the spread of the malaria parasite from humans to mosquitoes. Participants received either the …

This large Phase 3 trial tested whether combining three antimalarial drugs works better than the standard two-drug treatments for uncomplicated malaria in African children. Over 2,500 children aged 6 months to 12 years received either a triple or standard therapy. The goal was to…

This Phase 2 trial tested an experimental drug called INE963 in 52 adults with uncomplicated Plasmodium falciparum malaria. The main goal was to see how quickly the drug clears malaria parasites from the blood. Researchers also checked the 28-day cure rate. The study is part of a…

This study tested a single injection of an antibody called L9LS in healthy Kenyan children aged 5 months to 10 years. The goal was to see if it safely protects against malaria infection caused by the Plasmodium falciparum parasite. The trial involved 912 children and was complete…

This study tests whether giving school children preventive malaria medicine can reduce infections not only in them but also in younger siblings at home. About 1,000 students in rural Malawi will receive either one of two drug combinations or no preventive treatment. Researchers w…

This study tested a new drug called MAM01 to see if it is safe and could help prevent malaria for at least 4 months. It involved 125 healthy adults and children living in parts of Africa where malaria is common. Researchers gave different doses of MAM01 or a placebo and monitored…

This study tested whether giving antimalarial drugs to everyone in high-risk villages and forest workers could lower malaria cases in Thailand. Over 14,000 people took part. The goal was to see if this approach reduces infections from both Plasmodium falciparum and Plasmodium viv…

This early-stage trial is testing a new drug called GSK4024484 in 156 healthy adults to see if it is safe and how the body handles it. Researchers will also check if food affects the drug. The goal is to gather safety information before testing it in people with malaria.

This study looked at whether malaria parasites that are resistant to artemisinin drugs spread more easily after standard treatment. Researchers treated 160 people in Uganda who had malaria with either artemether-lumefantrine or dihydroartemisinin-piperaquine. They then used mosqu…

This completed study looked at how the malaria drug artesunate works in 90 Ugandan children aged 6 months to 14 years with severe malaria. Researchers measured drug levels in the blood and tracked vital signs like temperature and blood pressure to see how the body responds. The g…

This study tests a single injection of a new long-acting malaria drug called MMV371 in 32 healthy adults. The main goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored for about 12 weeks for side effects…

This study looked at whether the malaria parasite in Ethiopia is becoming resistant to artemisinin, the main drug used to treat it. Researchers tested 277 patients across five sites, checking if parasites were still in the blood three days after treatment and looking for a specif…

This completed study of 458 people in Burkina Faso aims to develop a tool that estimates how often malaria parasites switch to a form that can spread to mosquitoes. Researchers will measure certain biomarkers in blood samples from people with and without malaria symptoms. The goa…

This completed study in western Kenya looked at how well different malaria drugs work and whether the parasites are becoming resistant. Researchers tested four artemisinin-based combination therapies across 28 health facilities over 28 months, involving 316 people with uncomplica…

This study looked at 100 children in Congo with severe malaria to see if computer models could predict who might die. Researchers used blood tests and other data to build machine-learning algorithms. The goal is to help doctors make faster, better treatment decisions for the sick…

This study tested a new experimental drug called MMV367 in 12 healthy adults. Participants were intentionally infected with a controlled, low-level malaria infection to see how well the drug works and how safe it is. The goal was to measure how the body processes the drug and how…

This completed study from a French hospital looked at long-term after-effects in 56 adults who had severe malaria. Researchers used a questionnaire to check for physical, thinking, and emotional problems one year after diagnosis. The goal is to better understand and track these l…